Metabolic syndrome-like components and prostate cancer risk: Results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study

BJU International

Volumn 115, Issue 5, 2015, Pages 736-743

  Sourbeer, Katharine N ^a,b   Howard, Lauren E ^a,b   Andriole, Gerald L ^d   Moreira, Daniel M ^e   Castro Santamaria, Ramiro ^f   Freedland, Stephen J ^a,b,c   Vidal, Adriana C ^a,b,c  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e The Arthur Smith Institute for Urology   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

metabolic syndrome; prostate cancer; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; AZASTEROID; DUTASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ETHNICITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; BIOPSY; BLOOD; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

5-ALPHA REDUCTASE INHIBITORS; AGED; AZASTEROIDS; BIOPSY; DOUBLE-BLIND METHOD; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84927732106     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12843     Document Type: Article

References (37)

1. Alberti KG, Eckel RH, Grundy SM, et-al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
2. Kassi E, Pervanidou P, Kaltsas G, Chrousos G,. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48
3. Ford ES, Giles WH, Dietz WH,. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
5. Center MM, Jemal A, Lortet-Tieulent J, et-al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-1092
6. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK,. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-570
7. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B,. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010; 19: 2088-2096
8. Lund Haheim L, Wisloff TF, Holme I, Nafstad P,. Metabolic Syndrome predicts prostate cancer in a cohort of middle-aged norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774
9. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT,. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650
10. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, et-al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185-190
11. Pelucchi C, Serraino D, Negri E, et-al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011; 21: 835-841
12. Bhindi B, Locke J, Alibhai SM, et-al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol 2014; pii: S0302-2838(14)00125-0. doi: 10.1016/j.eururo.2014.01.040
13. Tande AJ, Platz EA, Folsom AR,. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102
14. Esposito K, Chiodini P, Capuano A, et-al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 2013; 36: 132-139
15. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI,. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 1181-1192
16. Xiang YZ, Xiong H, Cui ZL, et-al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res 2013; 32: 9
17. Morote J, Ropero J, Planas J, et-al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2013; 111: 1031-1036
18. Fukui M, Tanaka M, Kadono M, et-al. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008; 31: 930-931
19. Werny DM, Saraiya M, Gregg EW,. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006; 164: 978-983
20. Banez LL, Hamilton RJ, Partin AW, et-al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-2280
21. Andriole GL, Bostwick DG, Brawley OW, et-al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202
22. Freedland SJ, Hamilton RJ, Gerber L, et-al. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis 2013; 16: 254-259
23. De Nunzio C, Freedland SJ, Miano R, et-al. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011; 71: 1492-1498
24. Powell IJ, Bollig-Fischer A,. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol 2013; 27: 879-891
25. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60: 199-215
26. Tsilidis KK, Helzlsouer KJ, Smith MW, et-al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 2009; 20: 1739-1751
27. Platz EA, Till C, Goodman PJ, et-al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 2807-2813
28. Wallner LP, Morgenstern H, McGree ME, et-al. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int 2011; 107: 929-935
29. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE,. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152
30. Lawrence YR, Morag O, Benderly M, et-al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. P. Prostate Cancer Prostatic Dis 2013; 16: 181-186
31. Ma J, Li H, Giovannucci E, et-al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047
32. Chan JM, Stampfer MJ, Ma J, et-al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106
33. Lai GY, Giovannucci EL, Pollak MN, et-al. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control 2014; 25: 625-632
34. Li H, Stampfer MJ, Mucci L, et-al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010; 56: 34-43
35. Hamilton RJ, Banez LL, Aronson WJ, et-al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116: 3389-3398
36. Grossmann M, Wittert G,. Androgens, diabetes and prostate cancer. Endocr Relat Cancer 2012; 19: F47-62
37. Thomas JA 2nd, Gerber L, Banez LL, et-al. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev 2012; 21: 576-581